Compounded vs. Brand-Name GLP-1s in 2026: What Changed and What It Means for Your Prescription
Compounded semaglutide and tirzepatide did not simply become “illegal” in 2026. What changed is that the national drug shortages that allowed pharmacies to produce large quantities of compounded GLP-1 medications ended. That substantially narrowed when compounded versions can be made and intensified federal scrutiny of companies marketing them as inexpensive substitutes for Wegovy, Ozempic, Zepbound or Mounjaro.
A compounded GLP-1 may still be appropriate for an identified patient whose medical needs cannot be met by an available FDA-approved product. It is not, however, an FDA-approved generic version of the brand-name medication.
For patients in Wesley Chapel, Lutz, Land O’ Lakes and the surrounding Tampa Bay area, the practical question is no longer simply whether a clinic offers compounded semaglutide or tirzepatide. Patients need to know why the compounded medication is being prescribed, which pharmacy made it, how its concentration is measured and whether the prescription satisfies current patient-specific compounding requirements.
At South Beach Wellness Center, Maribel Dixon, MSN, APRN, FNP-C, evaluates medication selection as part of the patient’s broader metabolic and primary care plan. She is an autonomous, board-certified family nurse practitioner with experience in internal medicine, chronic disease management, medical weight loss and hormone therapy.
What Changed for Compounded GLP-1 Medications?
The extraordinary availability of compounded semaglutide and tirzepatide was largely a consequence of drug shortages.
When an FDA-approved medication appears on the FDA Drug Shortages List, federal law allows certain pharmacies and outsourcing facilities more latitude to compound versions of that medication because the approved product is not considered commercially available in the usual sense.
That shortage-based exception is no longer broadly available for semaglutide or tirzepatide.
The FDA determined that the tirzepatide injection shortage was resolved on December 19, 2024. The semaglutide injection shortage was declared resolved on February 21, 2025. The agency provided temporary enforcement-discretion periods to reduce disruption, but those periods ended in 2025.
By 2026, the regulatory environment had shifted from accommodating shortage-related supply gaps to scrutinizing whether compounded GLP-1 products were being produced and promoted within the much narrower boundaries of federal compounding law.
The FDA Is Targeting Mass-Marketed Copies
In February 2026, the FDA announced plans to restrict active pharmaceutical ingredients intended for non-FDA-approved GLP-1 products that were being mass-marketed as alternatives to approved medications.
The agency also challenged promotional claims suggesting that compounded products were generic, clinically proven or equivalent to FDA-approved medications. FDA warning letters issued in 2026 specifically addressed companies making false or misleading claims about compounded semaglutide and tirzepatide.
This distinction matters because “compounded” and “generic” are not interchangeable regulatory categories.
An FDA-approved generic medication must meet federal approval requirements and demonstrate that it provides the same clinical benefit and risks as the reference drug. A compounded medication is not reviewed or approved by the FDA for safety, effectiveness, manufacturing consistency or therapeutic equivalence before it reaches the patient.
A vial labeled “compounded semaglutide” is therefore not generic Wegovy or generic Ozempic. A vial labeled “compounded tirzepatide” is not generic Zepbound or generic Mounjaro.
Can Compounded Semaglutide or Tirzepatide Still Be Prescribed?
Yes, but the circumstances are narrower than they were during the shortages.
Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a state-licensed pharmacy or physician may compound medication for an identified individual patient based on a valid prescription. The compounder generally may not regularly produce large amounts of medication that are essentially copies of commercially available drugs.
A compounded product may fall outside the “essentially a copy” restriction when the prescriber determines and documents that a specific change produces a significant clinical difference for that particular patient.
That is a patient-specific medical standard. It is not a blanket exception based on lower price, broader profit margins or a general preference for multidose vials.
What Could Constitute a Significant Difference?
A legitimate clinical difference might involve a formulation change required because the patient cannot use an available approved product. The prescriber must determine that the change is significant for the identified patient and document that determination appropriately.
The existence of a different concentration or the addition of another ingredient does not automatically create a meaningful clinical difference.
The FDA has specifically warned that adding an ingredient such as vitamin B12 to semaglutide does not necessarily prevent the compounded drug from being considered essentially a copy. The complete formulation, strength, route of administration and documented patient need remain relevant.
This is an important change from the way many compounded GLP-1 programs were marketed during the shortage. “Our formula includes B12” is not, by itself, a sufficient explanation of why a patient needs a compounded medication.
What Is the Difference Between a 503A Pharmacy and a 503B Outsourcing Facility?
The terms 503A and 503B refer to different sections of federal compounding law.
| Compounding category | Basic operating model | Important GLP-1 limitation |
| 503A pharmacy | Compounds medication for an identified patient pursuant to a prescription | Cannot regularly produce large quantities that are essentially copies of commercially available drugs unless applicable patient-specific requirements are satisfied |
| 503B outsourcing facility | FDA-registered facility that may produce medication for healthcare facilities without first receiving an individual prescription | May generally use bulk substances only when the drug is on the shortage list or the substance appears on the FDA’s 503B bulks list |
Unlike 503A pharmacies, 503B outsourcing facilities are subject to current good manufacturing practice requirements. Registration as a 503B facility does not mean every medication it produces is FDA approved, nor does registration automatically authorize that facility to mass-produce semaglutide or tirzepatide.
As of August 2026, semaglutide and tirzepatide are not on the FDA Drug Shortages List or the 503B bulks list.
In April 2026, the FDA went further and proposed formally excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list after concluding that the available evidence did not demonstrate a clinical need for outsourcing facilities to compound them from bulk substances. The FDA’s published materials continue to identify this as a proposed determination rather than a completed final rule.
The FDA has already issued warning letters to outsourcing facilities that compounded tirzepatide from bulk drug substance when tirzepatide was neither in shortage nor included on the 503B bulks list.
Brand-Name and Compounded GLP-1s Are Not Evaluated the Same Way
Brand-name medications such as Wegovy and Zepbound are manufactured according to an FDA-reviewed formulation, strength, delivery system and labeling standard. Clinical trials establish the dosing schedule, expected benefits, known adverse effects and medication-specific warnings.
Compounded medications do not undergo that same premarket review.
This does not mean every compounded medication is defective. Compounding remains an important part of medicine when a commercially available product cannot meet an individual patient’s needs.
It does mean that the prescriber and patient must evaluate risks that are largely standardized in an approved product but may vary among compounded products.
These differences can include:
- The source and quality of the active pharmaceutical ingredient
- The concentration inside the vial
- Whether dosing instructions use milligrams, milliliters or syringe units
- The size and type of syringe provided
- Sterility and manufacturing controls
- Shipping temperature
- Beyond-use dates and storage instructions
- Whether adverse events are required to be reported to the FDA
These are not administrative details. They directly affect whether the patient receives the intended dose.
The Most Immediate Risk May Be a Dosing Error
FDA-approved GLP-1 injection pens are designed to deliver a defined dose. Many compounded products are supplied in multidose vials that require patients to draw medication into a syringe.
The concentration of one pharmacy’s product may differ from another’s. Even the same pharmacy may dispense more than one concentration.
As a result, “20 units” does not identify a medication dose unless the concentration is also known. Twenty units from one vial can contain a different number of milligrams than 20 units from another vial.
The FDA has received reports of patients and healthcare professionals confusing milligrams, milliliters and syringe units. Some errors caused patients to administer substantially more semaglutide than prescribed, resulting in severe nausea, vomiting, abdominal pain, dehydration, pancreatitis, gallstones, fainting and hospitalization.
A safe compounded prescription should state the medication dose in milligrams and provide clear instructions for translating that dose into the correct injection volume for that specific concentration.
A text message that simply tells a patient to “increase from 20 to 40 units” is not adequate medication management when the patient cannot verify the concentration or intended milligram dose.
Semaglutide Salt Forms Are Another Warning Sign
The active ingredient used in FDA-approved semaglutide medications is semaglutide base.
The FDA has warned that some compounded products may use semaglutide sodium or semaglutide acetate. These salt forms are chemically different active ingredients. The agency has stated that it lacks information showing that the salt forms have the same chemical and pharmacologic properties as the semaglutide used in approved medications and is unaware of a lawful basis for using these forms in compounding.
Patients should therefore ask what form of semaglutide is contained in the product. The word “semaglutide” on a promotional webpage is not a sufficient answer.
More Adverse Events Are Being Reported
As of May 31, 2026, the FDA had received 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide.
These reports do not prove that the compounded medication caused every event. They also cannot be used to calculate a complication rate because the total number of exposed patients is uncertain.
The FDA notes that adverse events are probably underreported because many state-licensed compounding pharmacies are not federally required to submit adverse-event reports.
The proper conclusion is not that every compounded product is unsafe. It is that the safety evidence is less complete, product consistency may vary and the reporting system cannot provide the same level of surveillance available for approved medications.
Shipping and Product Identity Matter More Than Most Patients Realize
Injectable semaglutide and tirzepatide products require appropriate storage. The FDA has received complaints about compounded GLP-1 medications arriving warm or with inadequate refrigeration.
The agency has also identified fraudulent products bearing the name of a pharmacy that did not actually make the medication. In other cases, the pharmacy identified on the label did not exist.
Patients should not inject a product when:
- The medication arrived warm despite instructions requiring refrigeration
- The label contains spelling errors or an incomplete pharmacy address
- The pharmacy cannot confirm that it produced the medication
- The concentration is missing or unclear
- The vial looks different after a refill and no explanation was provided
- The instructions do not identify the dose in milligrams
- The seller describes the product as “research use only”
Retatrutide and cagrilintide are not FDA-approved drugs and cannot lawfully be used in compounding under current federal law. Products sold directly to consumers as “research peptides” should not be treated as legitimate prescription alternatives.
Is a Brand-Name GLP-1 Always the Better Choice?
An available FDA-approved medication is generally preferred when it can meet the patient’s medical needs.
That preference is not based solely on brand recognition. The approved product offers a standardized formulation, validated delivery system, FDA-reviewed prescribing information and clinical trial evidence tied to a specific dose.
Cost and access remain legitimate barriers. However, lower cost does not erase the clinical and regulatory differences between the products.
The better question is not, “Which one is cheaper?” It is, “Which option gives this patient the clearest balance of medical appropriateness, product quality, affordability and continuity?”
A patient who cannot sustain the price of a brand-name medication needs a realistic plan. That plan may involve manufacturer self-pay programs, insurance authorization, a different approved medication, reconsideration of the treatment strategy or, in an appropriate patient-specific situation, a lawfully compounded product.
Questions Patients Should Ask About a Compounded GLP-1
Before filling a compounded semaglutide or tirzepatide prescription, the patient should be able to answer five questions.
Why Do I Need the Compounded Version?
The explanation should identify the patient-specific medical reason, not merely state that the compounded product is less expensive.
Which Pharmacy Is Making It?
The patient should receive the pharmacy’s legal name, location and licensing information. FDA registration applies to 503B outsourcing facilities, but FDA registration does not mean the compounded medication itself is approved.
What Exactly Is in the Vial?
The label should identify the active ingredient, concentration, total volume and any additional ingredients. For semaglutide, patients should confirm that the product does not use semaglutide sodium or semaglutide acetate.
What Is My Dose in Milligrams?
Syringe units describe volume, not the actual medication dose. The patient should understand both the prescribed milligrams and the corresponding injection volume.
What Happens if the Concentration Changes?
The prescribing practice should review the new instructions before the patient injects medication from a refill with a different concentration.
South Beach Wellness Perspective
The decision between a compounded and brand-name GLP-1 should not be isolated from the rest of the patient’s health.
Maribel Dixon evaluates whether the medication is appropriate in the context of glucose control, blood pressure, kidney and liver function, digestive symptoms, medications, hormone concerns, sleep, nutritional intake and long-term weight management goals.
This is particularly important when a patient has already experienced severe constipation, recurrent vomiting, suspected delayed gastric emptying or difficulty maintaining hydration. Changing the source of the medication does not correct an inappropriate dose or an unrecognized gastrointestinal condition.
A functional medicine approach should not mean automatically adding vitamins to a compounded formula or prescribing a “custom blend.” It should mean identifying the biological, behavioral and medical factors influencing the patient’s weight and using the safest evidence-based treatment that fits the complete clinical picture.
At South Beach Wellness Center, GLP-1 treatment is integrated with medical weight management, hormone care and direct primary care rather than treated as a standalone monthly transaction.
Frequently Asked Questions
Are compounded GLP-1 medications illegal in 2026?
Not categorically. Patient-specific compounding can remain permissible when federal and state requirements are satisfied. The broad shortage-based ability to mass-produce copies of semaglutide and tirzepatide has ended.
Is compounded semaglutide the same as Wegovy?
No. A compounded semaglutide product is not FDA-approved Wegovy and is not an FDA-approved generic equivalent.
Can a pharmacy add B12 and call the medication customized?
A pharmacy may formulate a medication with an additional ingredient when legally and clinically appropriate. Adding B12 does not automatically establish the significant patient-specific difference required to avoid the restrictions on essentially copying a commercially available drug.
Is a 503B compounded product FDA approved?
No. A 503B outsourcing facility registers with the FDA and is subject to federal manufacturing requirements, but its compounded medications are not individually FDA approved.
Should I stop taking my compounded medication?
Patients should not abruptly change a prescription solely because of general information online. They should ask the prescribing clinician to explain the medical rationale, dispensing pharmacy, formulation, concentration and current legal basis for the prescription.
Medical Disclaimer
This article is for educational purposes and does not provide legal advice or replace individualized medical care. Federal and state compounding requirements can change. Medication decisions should be made with a qualified healthcare provider who has reviewed the patient’s medical history, current prescriptions and treatment goals.
